Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01CRB
|
|||
| Former ID |
DAP000808
|
|||
| Drug Name |
L-Tyrosine
|
|||
| Synonyms |
DTY; Rxosine; Tirosina; Tyr; Tyrosine; Tyrosinum; Tirosina [Spanish]; Tyrosine Power; Tyrosinum [Latin]; Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs; L-Tyrosin; L-Tyrosine hydrochloride; Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide; P-Tyrosine; TYR NH3+ COOH; Tyrosine (VAN); Tyrosine [USAN:INN]; Free-Form L-Tyrosine; H-Tyr-OH; L-Tyrosine (9CI); L-Tyrosine (JAN); L-Tyrosine, homopolymer; L-Tyrosine, monomer; L-p-Tyrosine; Melanin synthesized from Tyr substrate catalyzed by tyrosinase, brominated with N-bromosuccinimide; Tyrosine (USP/INN); Beta-(p-Hydroxyphenyl)alanine; Melanin synthesized from Tyr substrate catalyzed by tyrosinase for 6 hrs, oxidized with hydrogen peroxide, <3 kd fraction; Tyrosine, L-(8CI); DD69927C-C6A8-4BC6-8E9A-0AB423B176E7; L-(-)-Tyrosine; Melanin synthesized from Tyr substrate catalyzed by tyrosinase, sulfonated using sulfur trioxide/DMF complex for 1.5-7 hours; Alpha-Amino-beta-(4-hydroxyphenyl)propionic acid; L-2-Amino-3-p-hydroxyphenylpropanoic acid; (-)-alpha-Amino-p-hydroxyhydrocinnamic acid; (S)-2-Amino-3-(4-hydroxyphenyl)propionic acid; (S)-2-Amino-3-(p-hydroxyphenyl)propionic acid; (S)-3-(p-Hydroxyphenyl)alanine; (S)-Tyrosine; (S)-alpha-Amino-4-hydroxybenzenepropanoic acid; 2-Amino-3-(p-hydroxyphenyl)propionic acid; 3-(4-Hydroxyphenyl)-L-alanine; 3-(p-Hydroxyphenyl)alanine; 4-Hydroxy-L-phenylalanine; 4ts1
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Malnutrition [ICD-11: 5B50-5B71] | Approved | [1], [2] | |
| Therapeutic Class |
Dietary supplement
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C9H11NO3
|
|||
| Canonical SMILES |
C1=CC(=CC=C1CC(C(=O)O)N)O
|
|||
| InChI |
1S/C9H11NO3/c10-8(9(12)13)5-6-1-3-7(11)4-2-6/h1-4,8,11H,5,10H2,(H,12,13)/t8-/m0/s1
|
|||
| InChIKey |
OUYCCCASQSFEME-QMMMGPOBSA-N
|
|||
| CAS Number |
CAS 60-18-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
3382, 585619, 585656, 608132, 817482, 817486, 817487, 817488, 817489, 823160, 828554, 832231, 841729, 854649, 3134840, 7847090, 7887220, 7890924, 8026808, 8028352, 8028353, 8144790, 8153780, 10529154, 11528398, 14710671, 15147336, 15195185, 24697644, 24697646, 24889931, 24900164, 24900206, 24900543, 24901863, 25622129, 26702499, 26711663, 26711664, 26711665, 26718889, 26719042, 29215265, 29215266, 29225067, 46394031, 46394400, 46504669, 46507885, 48416689
|
|||
| ChEBI ID |
CHEBI:17895
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [3] | |||
| Microbial Enzyme | Decarboxylase | |||
| Metabolic Reaction | Carboxyl group removal | |||
| Description | L-tyrosine can be metabolized by the decarboxylase of gut microbiota through carboxyl group removal. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tyrosine 3-monooxygenase (TH) | Target Info | Binder | [4], [5] |
| BioCyc | Catecholamine biosynthesis | |||
| KEGG Pathway | Tyrosine metabolism | |||
| Metabolic pathways | ||||
| Dopaminergic synapse | ||||
| Prolactin signaling pathway | ||||
| Parkinson's disease | ||||
| Cocaine addiction | ||||
| Amphetamine addiction | ||||
| Alcoholism | ||||
| Panther Pathway | Adrenaline and noradrenaline biosynthesis | |||
| Parkinson disease | ||||
| Dopamine receptor mediated signaling pathway | ||||
| Nicotine pharmacodynamics pathway | ||||
| Pathwhiz Pathway | Catecholamine Biosynthesis | |||
| Pathway Interaction Database | ATF-2 transcription factor network | |||
| AP-1 transcription factor network | ||||
| p38 signaling mediated by MAPKAP kinases | ||||
| Alpha-synuclein signaling | ||||
| WikiPathways | Monoamine Transport | |||
| SIDS Susceptibility Pathways | ||||
| Biogenic Amine Synthesis | ||||
| Dopaminergic Neurogenesis | ||||
| Metabolism of amino acids and derivatives | ||||
| Dopamine metabolism | ||||
| Parkinsons Disease Pathway | ||||
| Nicotine Activity on Dopaminergic Neurons | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4791). | |||
| REF 2 | Drug information of L-Phenylalanine, 2008. eduDrugs. | |||
| REF 3 | Gut Reactions: Breaking Down Xenobiotic-Microbiome Interactions. Pharmacol Rev. 2019 Apr;71(2):198-224. | |||
| REF 4 | Effect of metals and phenylalanine on the activity of human tryptophan hydroxylase-2: comparison with that on tyrosine hydroxylase activity. Neurosci Lett. 2006 Jul 3;401(3):261-5. | |||
| REF 5 | In situ and in vitro evidence for DCoH/HNF-1 alpha transcription of tyrosinase in human skin melanocytes. Biochem Biophys Res Commun. 2003 Feb 7;301(2):610-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.